Windlas Biotech Limited — Updates, 11-02-2025: Press Release

Windlas Biotech Limited reported strong financial results, marking a significant milestone with the highest revenue quarter for the eighth consecutive time. For 9M FY25, revenue reached Rs. 557.2 crore, reflecting a 21.2% year-on-year growth, while Q3 FY25 revenue stood at Rs. 195 crore, a 20.2% YoY increase. The Trade Generics and Institutional vertical excelled, achieving record revenues of Rs. 126.6 crore for 9M FY25, up 44% YoY, and Rs. 49.6 crore in Q3 FY25, surging 74% YoY.

The company saw its EBITDA rise to Rs. 68.6 crore for 9M FY25 (12.3% margin) and Rs. 24.6 crore for Q3 FY25 (12.6% margin), with corresponding YoY growths of 22.1% and 21.1%. Profit After Tax (PAT) for 9M increased by 8.5%, amounting to Rs. 44.7 crore, while Q3 PAT grew 3.2%, reaching Rs. 15.6 crore.

The company remains poised for continued growth, bolstered by the successful GMP certification of its injectable facility and a strategic plant expansion that is now operational. Investors should maintain a close watch on the positive momentum generated from the diverse product portfolio and expanding market reach, positioning Windlas Biotech for sustained future growth.